Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre

Letter Dermatology

A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

M. C. Fargnoli et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Letter Dermatology

Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

E. Nettis et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F. M. Ariens et al.

Summary: This study aimed to investigate the long-term effectiveness and safety of dupilumab in patients with treatment-refractory atopic dermatitis. The results showed a continuous improvement in clinical outcome measures during the 52-week follow-up period, with some patients experiencing adverse reactions, suggesting caution in the use of dupilumab.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre

Firas Constantin Kreeshan et al.

Summary: The study conducted in a tertiary center showed that dupilumab is an effective and safe treatment option for atopic dermatitis. Clinical response continued to improve past 16 weeks, and laboratory abnormalities were not felt to be secondary to dupilumab.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Letter Dermatology